Piper Sandler analyst Jason Bednar downgraded Pulmonx (LUNG) to Neutral from Overweight with a price target of $2.50, down from $9, following the Q2 report. The company posted its sixth consecutive quarter of decollation in the high-margin U.S. business. Piper no longer has confidence in management’s updated full-year outlook or that Pulmonx can return to 15%-20% sales growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG: